Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multicenter, dose-escalation trial of VS-4718, a focal
adhesion kinase inhibitor, in subjects with metastatic non-hematologic malignancies. This
clinical study is comprised of 2 parts: Part 1 (Dose Escalation) and Part 2 (Expansion). The
purpose of this study is to evaluate the safety (including the recommended Phase II dose),
pharmacokinetics (the amount of VS-4718 in your blood) and the anti-cancer activity of
VS-4718. The pharmacodynamic effects (genes or proteins that may predict or show how your
body may respond to VS-4718) will also be examined in tumor biopsies and blood samples.